Background. (1,3)-β-D-glucan (BG) is a biomarker for invasive candidiasis (IC). The usefulness of BG level as a prognostic marker of treatment outcome is not well characterized.
The incidence of invasive candidiasis in the United States has been increasing over the past 2 decades [1] . In addition, Candida species currently accounts for the fourth most common cause of nosocomial bloodstream infections in the United States [1] . Invasive candidiasis (IC) is a life-threatening infection associated with high mortality rates [2, 3] . Delaying the appropriate antifungal treatment of IC while awaiting blood culture results has been associated with increased hospital mortality [4] . Currently, a positive blood culture for Candida species remains the gold standard of diagnosing IC. However, it may take several days for the detection and final species identification of most yeast [5] . Early and rapid serologic methods for the diagnosis and evaluation of IC outcomes have recently been evaluated. One of the developed biomarkers is (1,3)-β-D-Glucan (BG), which is a major cell wall component of almost all fungi except for Zygomycetes and Cryptococcus species [6, 7] . An assay to measure serum BG was established by Obayashi and colleagues in 1995 as a marker of invasive fungal infections (IFI) [8] . Fungitell (Associates of Cape Cod, Inc) is an assay kit approved by the US Food and Drug Administration (FDA) for BG detection. The test is based on the activation of the coagulation cascade by BG [9] . Currently, BG detection has been widely used as a promising diagnostic tool for IFI [9] [10] [11] [12] [13] [14] and was included as an indirect microbiological criteria for the diagnosis of probable IFI in the revised definitions of IFI from the European Organization for the Research and Treatment of Cancer/Mycoses Study Group (EORTC/MSG) in 2008 [15] . In a recent meta-analysis of 16 studies involving 2979 patients (594 with proven and probable IFI), serum BG was effective in detecting patients with IFI with a pooled sensitivity of 76.8% (95% confidence interval [CI], 67.1%-84.3%) and a pooled specificity of 85.3% (95% CI, 79.6%-89.7%) [16] .
Consecutive measurements of BG levels may be a valuable tool in monitoring and predicting therapeutic outcomes in patients with IFI. Correlation between BG levels with clinical and microbiological outcomes has been observed in patients with IFI and Pneumocystis jiroveci pneumonia (PJP) [12, [17] [18] [19] . However, studies have also shown that BG did not reflect the severity of patients with PJP [20, 21] . Until recently, the relationship between BG levels and treatment responses in patients with IC has not been well characterized. We therefore conducted a study to evaluate the correlation of serial monitoring of serum BG levels with treatment responses in patients with proven IC. Additionally, we also determined a BG cutoff level for predicting treatment outcomes.
MATERIALS AND METHODS

Patients
Two hundred fifty-seven patients with proven candidemia/IC, selected from patients that were enrolled in a Pfizer clinical trial evaluating anidulafungin therapy for candidemia and IC in the United States, consented to participate in the study. The inclusion criteria included male and female patients (≥18 years) with or without neutropenia (absolute neutrophil count <500 cells/µL) who had the diagnosis of candidemia (at least 1 blood culture positive for yeast) or proven IC with tissue infections ( positive culture for yeast from a normally sterile site), according to EORTC/MSG criteria [15] . Patients with chronic refractory neutropenia (defined as absolute neutrophil count <500 cells/µL for 28 days prior to the baseline visit), fungal endophthalmitis, endocarditis, meningitis, osteomyelitis, or with prosthetic devices as suspected sites of infection without device removal within 24 hours of study entry were excluded from the study. Patients were allowed to receive up to 48 hours of antifungal therapy prior to baseline. All patients were treated with intravenous anidulafungin for at least 5 days and up to a maximum of 28 days. When possible, patients were de-escalated to an oral antifungal therapy of either voriconazole or fluconazole on any day between days 6 and 28, based on the species of Candida isolated and the treatment response. The primary endpoint of the study was overall treatment outcome at the end of all therapy, which consisted of a combination of clinical and microbiological responses. Responses to treatment were classified as treatment success (resolution or significant but incomplete resolution of signs and symptoms of Candida infection, with follow-up culture result negative for Candida spp.) and failure (no significant improvement or death, or follow-up culture positive for Candida spp.). Serum BG values were measured at baseline, whenever blood cultures were drawn, which included a daily set until a negative culture, at the end of therapy, and at 2 and 6 weeks after end of treatment.
The institutional review committee of each participating site approved the study with its ClinicalTrials.gov identifier NCT00496197.
BG Assay
Serum BG was measured using the Fungitell assay according to the manufacturer's instructions. Briefly, the assays were performed in a microtiter plate. Five microliters of each serum sample was pretreated with 20 µL of the alkaline reagent (0.25 M KOH and 1.2 M KCl) for 10 minutes at 37°C in order to convert triple-helix glucans to single-stranded glucans (which are more reactive in the assay) and also to inactivate the serine proteases and inhibitors (which can interfere with the result). One hundred microliters of the Fungitell reagent was added to each well. The microplate was inserted into an incubating (37°C) plate reader. The assay was monitored at 405 nm kinetically for 40 minutes at 37°C. Data were collected and calculated as a mean rate of optical density change for all points between 0 and 40 minutes. BG values <60 pg/mL were interpreted as being negative, >80 pg/mL as being positive, and 60-79 pg/mL as being indeterminate.
Statistical Methods
The mean and median of initial and final BG values in patients with either success or failure outcome were calculated. The initial and final BG levels of each group were compared. Initial BG sample was defined as the one collected at the baseline visit, and the final BG sample was defined as the last available BG in each patient. Patients were included in the analysis if they had at least 2 consecutive BG level measurements. Serial BG levels were plotted over time and Microsoft Excel software was used to calculate the best linear fit. Negative slopes of BG levels represented decreased BG levels and positive slopes represented increased BG levels. Overall outcome and serological outcome were compared. Two-by-two contingency tables were analyzed with Fisher exact test. Sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) were determined. A value of P < .05 was considered significant. A receiver operating characteristic (ROC) curve was constructed to illustrate the cutoff value for initial BG in order to determine treatment outcomes.
RESULTS
Two hundred fifty-seven subjects with candidemia and/or proven IC with tissue infections were enrolled in the study. Fifty-four patients were found to have less than 2 BG levels measured and thus were excluded from this study. In total, 203 patients who had a minimum of 2 BG levels in the study were evaluated. Baseline demographic characteristics, the species of Candida isolated, and sites of infection are shown in Table 1 . Of the 203 subjects with candidemia or tissue infections, 88.7% had at least 1 positive BG result with a cutoff value of at least 80 pg/mL. Sixty-seven percent of patients received some antifungal therapy prior to enrollment. Overall treatment success was found in 172 patients (85%). The initial and final BG assay results for patients with clinical success and clinical failure are shown in Table 2 . For the successfully treated patients, mean ± SD initial and final BG levels were 573 ± 681 pg/mL and 499 ± 635 pg/mL (P = .03), respectively. In the treatment-failure patients, the BG levels were 1224 ± 1585 pg/mL and 1293 ± 1283 pg/mL (P = .29), respectively. In the 170 patients with candidemia alone, the mean ± SD initial and final BG levels in the successfully treated patients were 600 ± 709 pg/mL and 515 ± 670 pg/mL (P = .04), respectively. In contrast, the BG levels for the treatment-failure patients were 1318 ± 1696 pg/mL and 1404 ± 1353 pg/mL (P = .28), respectively. In the 30 patients with documented tissue infections, successfully treated patients had mean ± SD initial and final BG levels of 401 ± 509 pg/mL and 394 ± 424 pg/mL (P = .44), respectively. In the patients with documented treatment failures, the initial and final BG levels of 414 ± 103 pg/ mL and 453 ± 312 pg/mL (P = .42), respectively, were identified. Three patients were found to have both candidemia and tissue infection (mixed infection). Two out of 3 patients had successful treatment outcome but BG levels were decreased during follow up in all 3 patients. Sixteen percent (27/172) of the treatment-success group had an interpretative negative final BG level. Ninety-seven percent (30/31) of treatmentfailure patients had an interpretative positive final BG level.
Patients with successful treatment tended to have a negative slope in BG levels with a sensitivity, specificity, PPV, and NPV of 62%, 61%, 90%, and 22%, respectively, and likelihood ratio (LR) of 1.6. Although numbers are markedly smaller for noncandidemic patients, the correlation of the overall decrease in BG and successful outcome was better in patients with candidemia than in patients with tissue infections (sensitivity, specificity, PPV, and NPV were 64%, 65%, 91%, and 25%, respectively, for candidemia; and 46%, 50%, 86%, 13%, respectively, for IC with tissue infections). A positive slope for BG levels correlated with treatment failure with a sensitivity, specificity, PPV, and NPV of 61%, 62%, 22%, and 90%, respectively. An ROC of initial BG levels was generated ( Figure 1 ). The area under ROC curve of initial BG was 0.65 (95% CI, .54-.75) for overall treatment outcomes in patients with proven IC. Based on an initial BG of <416 pg/mL, we were able to predict treatment success (odds ratio 2.22; 95% CI, 1.02-4.84) with a sensitivity, specificity, PPV, and NPV of 62%, 58%, 89%, and 21%, respectively.
DISCUSSION
The kinetics of BG release from infected sites, the circulation, and clearance in humans remains poorly understood [12] . Using serial BG levels during follow up response to antifungal treatment has been observed in patients with IFI [12, 17, 22, 23] and PJP [18, 19, [24] [25] [26] . Previous studies for IFI have shown that a decrease in BG levels correlated with response to therapy and an increase in BG level was associated with treatment failure. Pazos et al. [12, 22] reported 6 hematological cancer patients with proven and probable IC and 5 patients with proven invasive aspergillosis that demonstrated an increasing or persistently high serum BG level even before clinical or microbiological confirmation of IFI. In addition, the levels declined with the patient's clinical response to antifungal therapy. Similarly, Senn et al. [17] demonstrated that BG levels became negative in 10 out of 12 neutropenic patients with acute leukemia and IFI who responded to treatment, while the BG levels increased in 2 patients who did not respond to therapy. Petraitiene et al. [23] described declining serum BG levels following micafungin administration in a rabbit model of Candida meningoencephalitis.
Serum BG kinetics have also been studied in patients with PJP. Shimizu et al. [18] showed that in 15 connective tissue disease patients with PJP, 5 nonsurvivors had statistically significant higher BG levels compared to 10 survivors (272 ± 60.7 vs 104 ± 28.9; P < .05). Marty et al. [19] showed that BG levels decreased after treatment, but remained elevated in 5 of 16 patients that were followed for 5 weeks. Cuetara et al. [24] demonstrated that 2 immunocompromised patients with PJP had decreasing levels of BG that corresponded to a successful outcome, whereas 1 patient who failed therapy had an increasing BG level. Held et al. [26] studied 18 immunosuppressed patients with PJP and found that 7 out of 8 patients (88%) who had clinical improvement on therapy had constantly decreasing BG levels; however, increasing BG levels reflected treatment failure in 44% of patients.
There are few studies showing that BG levels may not be suitable for monitoring responses to treatment. Watanabe et al. [20] evaluated BG levels before and after treatment in 42 AIDS patients with PJP; 16.7% of patients had normalized BG levels within 3 weeks of treatment. Koga et al. [21] also showed that BG levels dropped to normal range in only 3 of 17 AIDS patients with PJP at the completion of 4 weeks of treatment and in 7 of 17 patients at 6 weeks. Nevertheless, a negative BG level early after antifungal therapy may not be a good marker to define treatment response, because time to achieve a serological cure is usually several weeks after the end of treatment [25] .
In our study, we have evaluated the usefulness of consecutive serum BG measurements during therapy, in order to assess treatment response in patients with proven candidemia/ IC with tissue infections who received primarily echinocandin monotherapy. Obtaining multiple samples of BG does not only increase the sensitivity and specificity of the test for diagnosis [9] , but it also correlates with the clinical and microbiological outcomes as previously described [12, 17] . Currently, there is no standard method to determine the correlation of BG levels and treatment outcome. We have proposed the method of plotting serial BG levels over time. A negative slope of BG levels represented decreased BG levels and a positive slope of BG levels represented increased BG. Overall, decreasing levels of BG corresponded with a favorable response to antifungal therapy with the high PPV (90%). There is a discrepancy between sensitivity, specificity, and PPV, which may be explained by high prevalence rate of infection in our study. However, we have showed that, based on an LR of 1.6, if BG levels tend to decrease during therapy, it is 1.6 times more likely to have a successful treatment outcome. Patients who failed treatment tended to have increased BG levels with a high NPV (90%).
We attempted to evaluate the correlation between BG levels and outcomes by using a 5% reduction of the initial levels and found that less than 60% of successes had more than a 5% reduction of BG levels (data not shown). Therefore, we feel that using the slope of BG levels shows better correlation with outcomes than using an arbitrary percentage reduction or increase cutoff.
The site of infection may also influence BG levels and the correlation of BG and treatment outcome. Although successfully treated patients with both candidemia and tissue infections showed a decrease of mean BG levels and the failuretreatment group tended to have increasing BG levels, patients with tissue infections failed to show a significant drop in BG levels despite successful outcomes, and there was a discrepancy between median and mean BG levels in this group. The overall mean BG levels were lower in patients with tissue infections compared to patients with candidemia. However, the number of patients with tissue infection in our study was limited, which may affect the outcome of the test. Our study has shown that only 16% of successfully treated patients had a negative final BG result, which was comparable with a previous study [25] showing that a negative BG level may not be a suitable marker for a successful treatment outcome early after antifungal therapy.
It is important to note that an initial BG level of <416 pg/ mL has the potential to predict favorable outcome in patients with IC demonstrating a high PPV (89%). If the initial BG level was <416 pg/mL, 62% of patients were successfully treated, while if initial BG level was >416 pg/mL, only 38% of patients had successful outcome. Prior antifungal use may affect the cutoff value. We evaluated the cutoff values in both groups of patients who received and did not receive prior antifungal medications (data not shown) and found the proposed cutoff level in those with no prior antifungal therapy did not reliably predict outcome. However, the numbers are very small, thus we were unable to make strong conclusions from our data. This would be an interesting subject for a future study to evaluate different antifungal backgrounds and timing of therapy.
BG level fluctuations may be related to, at least in theory, an initial burst as the cell wall is disrupted, followed by a decrease in levels as yeast cells are no longer reproducing and BG is cleared. In this model, BG would generally trend down in a successfully treated patient and trend up in a patient failing therapy. However, there may be other variables involved, such as the use of a fungicidal versus fungistatic drug, the burden of disease, presence of a retained central venous catheter and biofilm [27] , extraneous sources of BG, and renal clearance. The exact kinetics of BG during fungal infection remain to be studied.
Our study had limited data on potential confounding factors, including catheter removal, previous antibiotic and antifungal use, treatment with albumin or immunoglobulin, renal insufficiency, sponges or gauze exposure, or hemodialysis, all of which may affect BG levels and the kinetics of BG. It is also very important to point out that these results can only be extrapolated to patients being initially treated with echinocandin monotherapy followed by fluconazole or voriconazole, as BG may theoretically behave differently in patients in whom other classes of antifungals are used initially or in combination. The study was not designed or powered to evaluate the usefulness of BG level as a survival predictor, but it would be very interesting to do so in a future study.
We present the results of a large study that explores the correlation between serum BG levels and treatment outcomes. Our study suggests that baseline and consecutive BG levels in patients with proven IC may be a useful prognostic marker to predict therapeutic outcomes and to monitor response to antifungal therapy with echinocandins. Further studies with other antifungals and looking prospectively at variables such as timing of antifungals and catheter removal are warranted. 
Notes
